Drug profile · INN
bexagliflozin
BRENZAVVY
bexagliflozin (BRENZAVVY) is a sodium/glucose cotransporter 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — bexagliflozin
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
bexagliflozin (BRENZAVVY) is a sodium/glucose cotransporter 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium/glucose cotransporter 2 inhibitor
Primary target: Sodium/glucose cotransporter 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is bexagliflozin?
bexagliflozin (BRENZAVVY) is a sodium/glucose cotransporter 2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for bexagliflozin?
BRENZAVVY is a marketed brand name for bexagliflozin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bexagliflozin?
bexagliflozin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.